Evaluating radiofrequency ablation and stabilization for metastatic spine lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to demonstrate the metabolic changes in spine lesions treated with a combination of radiofrequency ablation and augmentation. Patients with secondary osteolytic and mixed spine tumors, having one to three active lesions confirmed by PET-CT, will be enrolled. The treatment involves using a percutaneous ablation device (Osteocool-Medtronic) to target metabolically active lesions. Following treatment, patients will undergo a follow-up PET-CT to assess the effectiveness of the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* only patients with secondary osteolytic and mixed (lytic and sclerotic) spine tumors with one to three active lesions will be enrolled.
* lesions to be treated must be metabolically active on PET-CT performed during the last month.
* Patients will be informed and sould sign an inform consent.
* post treatment patients should submittes a new PET-CT in order to verify the activity of the treated area.

Exclusion Criteria:

\-

Where it's running

• 3rd Department of Radiology, NKUOA, General Hospital "LAIKON"
  Athens, Athens, Greece Recruiting

Study contacts

• Principal investigator: Alexios Kelekis, Md, Phd — National and Kapodistrian University of Athens
• Study coordinator: Alexis Kelekis, MD PHD, EBIR
• Email: akelekis@med.uoa.gr
• Phone: +302105831806

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Heart-friendly medicines to protect chest-area cancer patients from radiation damage

  This Phase 2 trial tests whether taking atorvastatin and lisinopril can reduce heart damage in adults with chest-area cancers who receive radiation therapy.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07685938

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

• Evolution of spinal care practices in Bordeaux

  This study will track how care for spine conditions changes over five years by collecting data from adults treated for spinal issues at a Bordeaux hospital.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07627282

• Endoscopic ultrasound-guided radiofrequency ablation for pancreatic and left adrenal lesions

  This will try EUS-guided radiofrequency ablation to control symptoms and hormone-related problems in adults with small pancreatic neuroendocrine tumors (including insulinomas) or certain left adrenal adenomas.

  Recruiting Herlev Hospital · Herlev, Capital Region · NCT07272187

• Radiofrequency ablation for severe leg vein disease in people 80 and older

  This will try radiofrequency ablation in people aged 80 and older with severe chronic venous insufficiency to see if it safely closes the leaking saphenous veins and improves symptoms and quality of life.

  Recruiting Chengdu University of Traditional Chinese Medicine · Chengdu, Sichuan · NCT07233616

• Spine tumor registry tracking outcomes after separation surgery and radiation

  This registry will collect information to see what outcomes adults with primary or metastatic spine tumors have after separation surgery followed by radiation.

  Recruiting at 5 sites Ohio State University Comprehensive Cancer Center · Indianapolis, Indiana and 4 other locations · NCT07225491

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.